Pharmaceutical company Moderna (NASDAQ:MRNA) has begun trials of its COVID-19 vaccine in Canadian children aged six months to less than 12 years.
The study will assess the safety and effectiveness of two doses of Moderna’s mRNA-1273 vaccine given 28 days apart. The trial will involve 6,750 children in the United States and Canada, the company said.
Moderna’s vaccine has already been authorized for emergency use in Americans and Canadians who are aged 18 and older. In a separate study that began in December, Moderna is also testing its mRNA-1273 vaccine in adolescents between the ages of 12 and 18 years old.
The latest study is being conducted in collaboration with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA).
